YNYevhenii Novodvorskyi

Yevhenii Novodvorskyi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yevhenii Novodvorskyi has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Triazin-5-ones Derivatives as Potential Antiseizure Medicines

    by Anatolii Demchenko, Artur Martynov, Volodymyr Zaitsev, Yevhenii Novodvorskyi, Oleh Yadlovskyi, Albina Mikhraliieva, Yulia Fedchenkova, Tatyana Bomko, Tatyana Nosalsky, Sergii Demchenko, et al.

    Introduction: Epilepsy is a major global health burden, affecting more than 70 million people worldwide. Approximately 20-30% of patients do not achieve adequate seizure control with currently available antiseizure medications. This study investigates novel triazin-5-one derivatives as potential antiseizure agents targeting the γ-aminobutyric acid (GABA) system. The compounds were designed to interact with GABAA receptors and inhibit GABA aminotransferase (GABA-AT), using lamotrigine as a reference antiseizure drug. This dual-target strategy may support the development of more effective therapies for drug-resistant epilepsy. Materials and Methods: Eighteen 6-(4-methoxybenzyl)-3-R-4H-[1,2,4]triazin-5-one derivatives (3a–r) were synthesized and characterized by 1H and 13C NMR spectroscopy, LC-MS, and elemental analysis. Molecular docking was performed against the GABAA receptor (PDB ID: 1OHV) and GABA-AT enzyme (PDB ID: 1SF2) to estimate binding affinity. GABA-AT inhibition was evaluated in vitro, and anticonvulsant activity was assessed in mouse models at doses equimolar to 10 mg/kg lamotrigine. Results: Compounds 3o, 3f, 3r, 3g, and 3h showed the highest predicted binding affinities for the GABAA receptor, with binding-energy magnitudes exceeding 10 kcal/mol. Compound 3h (3-(2,3-dimethylphenylamino)-6-(4-methoxybenzyl)-4H-[1,2,4]triazin-5-one) exhibited the lowest IC50 value for GABA-AT inhibition (30.50 ± 0.61 μM), comparable to that of lamotrigine (32.7 ± 0.7 μM). In the animal model, compounds 3f and 3h completely suppressed clonic and recurrent clonic-tonic seizures. Docking analysis indicated that 3h forms hydrogen bonds with Arg430 and Ile426 through the triazine oxygen atom and interacts with His44 through a triazine nitrogen atom. Discussion: The anticonvulsant effects of these 1,2,4-triazine derivatives appear to depend on the substituents at positions 3 and 6 of the heterocyclic ring. Their potential dual mechanism, involving both receptor modulation and enzyme inhibition, may contribute to their neurotropic activity. Compound 3r contains a defined pharmacophore incorporating tryptamine and triazine fragments, whereas the spatial requirements underlying the activity of compound 3h remain unclear and require further structural investigation. Conclusion: The study identifies novel triazin-5-ones, specifically compounds 3h and 3f, as promising candidates for the development of new antiseizure therapies. These derivatives demonstrate potency and efficacy comparable to lamotrigine and may offer a multi-target mechanism within the GABAergic system.

  • Open Access

    Synthesis and structure-activity relationship of 4,6-bis(pyrrolidin-1-yl)-1,3,5-triazines, their antiviral activity against yellow fever and Tacaribe viruses

    by Anatolii Demchenko, Artur Martynov, Yevhenii Novodvorskyi, Andrii Tsyhankov, Albina Mikhraliieva, Oleh Moskalenko, Oleh Yadlovskyi, Sergii Demchenko, Sergii Tsyhankov, Sergii Yarmoluk, et al.


  • Open Access

    Novel triazin-5-ones as potential antiseizure medicines

    by Artur Martynov, Anatolii Demchenko, Volodymyr Zaitsev, Yevhenii Novodvorskyi, Oleh Yadlovskyi, Albina Mikhraliieva, Yuliia Fedchenkova, Tatyana Bomko, Tatyana Nosalska, Sergii Demchenko, et al.

    Novel triazin-5-ones as potential antiseizure medicines Anxiety and related issues are major health and social concerns in developed countries, affecting 10–20% of the population. The lowest effective inhibitory concentrations for GABA-AT were observed for two compounds: 3h (30.50±0.61 µM) and 3r (44.76±0.49 µM). Their IC50 values were similar to those of lamotrigine. In vitro tests showed that compounds 3h and 3f had the lowest IC50 values for GABA-AT inhibition, at 30.50±0.61 and 44.58±0.54, respectively. The anticonvulsant activity of 6-(4-methoxybenzyl)-3-R-4H-[1,2,4] triazin-5-ones in a corral seizure model depends on modifications to substituents at positions three and six of the heterocyclic 1,2,4-triazine ring. Leading compounds, 3f (3-(4-Chlorophenylamino)-6-(4-methoxybenzyl)-4H-[1,2,4]triazin-5-one) and 3h (3-(2,3-Dimethylphenylamino)-6-(4-methoxybenzyl)-4H-[1,2,4]triazin-5-one), completely inhibit clonic and tonic-clonic seizures. Compound 3r, which contains both tryptamine and triazine fragments, has a clear pharmacophore structure. However, the spatial structure of the pharmacophore in compound 3h, with the lowest binding energy to GABAa and GABA-AT and the best performance in tests, is not yet fully understood.

  • Neurotropic Effects In Vivo of New Tryptamino-Triazines Compared to GABA Effectors

    by Anatoly Demchenko, Artur Martynov, Yevhenii Novodvorskyi, Oleh Yadlovskyi, Oleh Moskalenko, Tatyana Bomko, Tatyana Nosalsky, Sergii Demchenko, Sergiy Yarmoluk

    Anxiety and other neurotic disorders are significant medical and social issues, affecting 10-20% of people in developed countries, with an annual increase of over 10%. These conditions are becoming a greater concern due to treatment costs, missed work, decreased productivity, and their impact on relationships and socialization. As a result, developing effective treatments for neurotic disorders is a key goal in medicine and pharmacology. For the first time, we synthesized derivatives containing both tryptamine and triazine fragments and demonstrated their neurotropic activity, in particular their anxiolytic effect. When examining their binding using the docking method (Autodock Vina multiligand) to the GABAa receptor (PDB ID: 6X3X) and GABA-AT (PDB ID: 1SF2), compounds 4-11a-i showed minimal binding energies. In animal studies, compounds 9b and 11g demonstrated notable antianxiety effects, influencing behaviors such as approach to the arena center, grooming, and bolus count. Compound 11g 6-(4-chlorobenzyl)-3-[2-(6-methoxy-1H-indol-3-yl)-ethylamino]-4H-[1,2,4]triazin-5-one had the lowest IC50 value at 19.8 ± 0.62, indicating high potency, and appeared to function similarly to diazepam without impairing normal exploration or movement. Notably, 9b outperformed other tested drugs. Its derivative 11g displayed the lowest energy binding with GABAA receptor and GABA-AT, which likely accounts for its high activity.

  • Synthesis and evaluation of anti-yellow fever virus activity of new 6-aryl-3-R-amino-1,2,4-triazin-5(4H)-ones

    by Yevhenii Novodvorskyi, Roman Lesyk, Igor Komarov, Dmitry Lega, Iryna Zhuravel, Oleh Moskalenko, Volodymyr Sukhoveev, Anatolii Demchenko


  • Open Access

    Synthesis and antioxidant activity of 3-(2-R-ylidenehydrazinyl)-6-tert-butyl- 4H-[1,2,4]triazin-5-ones

    by Yevhenii Novodvorskyi, Dmitry Lega, Igor Komarov, Iryna Zhuravel, Oleg Moskalenko, Anatolii Demchenko

    Synthesis and structure elucidation of several series of new hydrazones containing 1,2,4-triazine-5-one core and their antioxidant activity are presented. The target compounds have been synthesized via interaction of either 4-amino-6-(tert-butyl)-3-hydrazinyl-1,2,4-triazin-5(4H)-one or 6-(tert-butyl)-3-hydrazinyl-1,2,4-triazin-5(2H)-one with a wide range of compounds with a carbonyl group in moderate to high yields. Molecular structures of the synthesized compounds were confirmed by NMR, C-13 NMR, and elemental analyses. The antioxidant activity of these compounds against ascorbic acid was screened to determine their potential as promising oxidative stress suppressors. Our data showed that hydrazones derived from 4-amino-6-(tert-butyl)-3-hydrazinyl-1,2,4-triazin-5(4H)-one are the most active antioxidants among all tested compounds. Furthermore, 3 compounds of this series have been proved to be twice as active as ascorbic acid does. The conclusions are substantiated for in-depth investigations of these derivatives as promising agents for the treatment of disorders accompanied by oxidative stress.